Brief: Regeneron Canada Says Libtayo Receives Health Canada Approval For Treatment Of A Type Of Carcinoma
06/08/2026 16:31
BRIEF-Regeneron Canada Says Libtayo Receives Health Canada Approval For Treatment Of A Type Of Carcinoma Aug 6 (Reuters) - Regeneron Canada:
REGENERON CANADA: LIBTAYO RECEIVES HEALTH CANADA APPROVAL FOR ADJUVANT TREATMENT OF HIGH-RISK CUTANEOUS SQUAMOUS CELL CARCINOMA
Source text: ID:nCNWj2k0ca
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement